Research Analysts Issue Forecasts for MDGL Q2 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Madrigal Pharmaceuticals in a report released on Wednesday, February 26th. Leerink Partnrs analyst T. Smith forecasts that the biopharmaceutical company will post earnings of ($2.59) per share for the quarter. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. Leerink Partnrs also issued estimates for Madrigal Pharmaceuticals' Q3 2025 earnings at ($1.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2029 earnings at $52.80 EPS.

Several other research firms have also issued reports on MDGL. B. Riley upgraded shares of Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and increased their price target for the stock from $236.00 to $422.00 in a research report on Thursday, February 27th. HC Wainwright lifted their price target on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Cantor Fitzgerald reissued a "neutral" rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Citigroup lifted their target price on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $375.75.

Remove Ads

Madrigal Pharmaceuticals Price Performance

NASDAQ:MDGL traded down $18.51 during trading hours on Monday, reaching $328.77. 344,823 shares of the company were exchanged, compared to its average volume of 441,473. The company has a market capitalization of $7.26 billion, a P/E ratio of -13.11 and a beta of -0.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The business has a 50 day moving average of $324.17 and a 200 day moving average of $287.02. Madrigal Pharmaceuticals has a 1-year low of $189.00 and a 1-year high of $377.46.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share for the quarter, topping the consensus estimate of ($4.32) by $1.61. The business had revenue of $103.32 million during the quarter, compared to analyst estimates of $97.81 million.

Insider Buying and Selling at Madrigal Pharmaceuticals

In related news, insider Carole Huntsman sold 347 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total transaction of $116,328.28. Following the completion of the sale, the insider now owns 10,438 shares of the company's stock, valued at $3,499,235.12. This trade represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Robert E. Waltermire sold 1,227 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $341.07, for a total transaction of $418,492.89. Following the sale, the vice president now directly owns 3,728 shares of the company's stock, valued at approximately $1,271,508.96. This trade represents a 24.76 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,787 shares of company stock valued at $7,351,029. 22.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in shares of Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 68 shares during the period. Kohmann Bosshard Financial Services LLC bought a new position in shares of Madrigal Pharmaceuticals in the fourth quarter valued at $70,000. Quest Partners LLC grew its holdings in shares of Madrigal Pharmaceuticals by 172.8% during the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock valued at $123,000 after buying an additional 368 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Madrigal Pharmaceuticals during the fourth quarter valued at about $141,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $164,000. Institutional investors own 98.50% of the company's stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.